Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rC19
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rC19 is a recombinant COVID-19 vaccine component that has been used in combination with other vaccines, such as high-dose seasonal influenza virus vaccines, to create multivalent or combination vaccines targeting both influenza and SARS-CoV-2. In these combinations (e.g., IIV-HD + rC19), the product is designed for the prevention of COVID-19 and influenza infections. The mechanism of action involves immunostimulation—eliciting an immune response against SARS-CoV-2 through presentation of recombinant viral antigens. The vaccine is typically administered via intramuscular injection and may be adjuvanted to enhance immunogenicity. Development efforts have included companies like Sanofi, with clinical trials reaching Phase I/II for both COVID-2019 infections and influenza virus infections[4][3].
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on rC19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rC19.